2,4-Difluorotoluene

We are 2,4-Difluorotoluene CAS:452-76-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 2,4-Difluorotoluene
Other Name: 2,4-Difluoro-1-methylbenzene
CAS No: 452-76-6
MF: C7H6F2
MW: 128.11900
Density: 1.12 g/mL at 25 °C(lit.)
Boiling point: 113-117 °C(lit.)
Flash point: 59 °F
Refractive index: n20/D 1.449(lit.)
Vapor Pressure: 0.272mmHg at 25°C
UN Number: UN1993
UN Proper Shipping Name: FLAMMABLE LIQUID, N.O.S.
Transport hazard class: 3
Packing group: II
 
Specification
Appearance: Colorless transparent liquid
Purity: ≥98%
Water: ≤0.5%
 
Application: Organic intermediates, pharmaceutical intermediates, agrochemical intermediates, OLED intermediates.
Package: 25kg/drum, packed in plastic drum or plastic coated iron drum.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

 2,4-Difluorotoluene


Related News: Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.2'-Deoxy-2'-fluorouridine CAS:784-71-4 Bulk drug substances mainly include vitamins, antibiotics, hormones, antipyretics and analgesics, among which vitamin C, erythromycin thiocyanate, penicillin, azithromycin, and semi-synthetic cephalosporins are the most concentrated products in the industry in terms of production and overcapacity.tert-butyl (S)-2-((aminooxy)methyl)pyrrolidine-1-carboxylate The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.1-fluoro-2,4-dinitrobenceno CAS:70-34-8 The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.

Related Products
Product Name
5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile View Details
1-Bromo-3,4,5-trimethoxybenzene View Details
Suberic Acid Monomethyl Ester View Details
2,3,4-Trimethoxybenzaldehyde manufacturer 2-Bromo-5-chloroanisole manufacturer 3-(TRIFLUOROMETHOXY)ANISOLE manufacturer 3-Amino-4-methylphenol manufacturer 2,3-Dimethyl-6-Nitro-2H-Indazole manufacturer